[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beihua Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,36,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":4},"100604760","ocs-products-based-on-exosome-technology-were-applied-in-the-recurrence-monitoring-study-after-the-initial-treatment-of-baseline-ca125-negative-ovarian-cancer-100604760",false,"NCT07153705","OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer","Inclusion criteria:\n\n1. Women over 18 years old;\n2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;\n3. ECOG \\\u003C 2;\n4. The expected survival period exceeds 6 months;\n5. CA125 ≤ 35 U\u002Fml before initial treatment;\n6. Undergo surgery and adjuvant chemotherapy;\n7. The period between diagnosis and enrollment does not exceed 8 weeks;\n8. Be willing to provide blood samples for OCS testing during the research process;\n9. Sign the informed consent form.\n\nExclusion criteria\n\n1. Have had other malignant tumors within the last five years;\n2. Have received any treatment for ovarian cancer;\n3. Benign ovarian mass;\n4. Non-primary ovarian tumors;\n5. Combined with other malignant tumors;\n6. Patients receiving neoadjuvant therapy;\n7. Pregnancy.","FEMALE","18 Years",{"count":18,"type":19},32,"ESTIMATED","OBSERVATIONAL","To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.",[23],"Ovarian Cancer","NOT_YET_RECRUITING","2025-08-26",{"date":27,"type":28},"2025-09-04","ACTUAL",{"date":30,"type":19},"2025-09-01",{"date":32,"type":19},"2026-04-01",{"name":34,"class":35},"Beihua Kong","OTHER",{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100242086","phase-3-tc-or-bep-in-treating-patients-with-malignant-ovarian-germ-cell-tumors-100242086","NCT02429687","TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors","A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors","MOGCT-01","Inclusion Criteria:\n\n* Age≤65 years; female, Chinese women;\n* Histologically confirmed ovarian stromal tumor, including the following cell types:\n\n  * Granulosa cell tumor\n  * Granulosa cell-theca cell tumor\n  * Sertoli-Leydig cell tumor (androblastoma)\n  * Steroid (lipid) cell tumor\n  * Gynandroblastoma\n  * Unclassified sex cord-stromal tumor\n  * Sex cord tumor with annular tubules\n* Newly diagnosed, stage IIA-IVB disease;\n\n  * Has undergone initial surgery (for diagnosis, staging, or cytoreduction) within the past 8 weeks.\n  * May or may not have measurable residual disease.\n* Laboratory tests: WBC≥4×10(9)\u002FL, NEU≥2×10(9)\u002FL, PLT≥80×10(9)\u002FL, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, BUN, Cr≤ normal\n* Performance status: Karnofsky score≥60;\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* With severe or uncontrolled internal disease, unable to receive surgery and\u002For unsuitable for chemotherapy;\n* History of organ transplantation, immune diseases;\n* History of serious mental illness, a history of brain dysfunction;\n* Drug abuse or a history of drug abuse;\n* Suffering from other malignancies;\n* Concurrently participating in other clinical trials\n* Unable or unwilling to sign informed consents;\n* Unable or unwilling to abide by protocol.","14 Years","65 Years",{"count":47,"type":19},129,"INTERVENTIONAL",[50],"PHASE3","Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.",[53,54,23],"Ovarian Germ Cell Cancer","Ovarian Neoplasms","RECRUITING","2023-04-22",{"date":58,"type":28},"2023-04-25",{"date":60,"type":4},"2015-04",{"date":62,"type":19},"2030-05",{"name":34,"class":35},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":44,"maxAge":45,"enrollmentInfo":72,"targetDuration":4,"studyType":48,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":81,"locationsCount":64},"100242087","phase-3-tc-or-bep-in-treating-patients-with-ovarian-malignant-sex-cord-stromal-tumors-100242087","NCT02429700","TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors","A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors","SCST-01",{"count":73,"type":19},132,[50],"Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant sex cord-stromal tumor patients after surgery.",[77,54,23],"Ovarian Sex Cord Stromal Tumor",{"date":58,"type":28},{"date":60,"type":4},{"date":62,"type":19},{"name":34,"class":35},""]